TradingKey

• Hewlett Packard Enterprise shares pulled back due to broad profit-taking and insider sales. • Technical indicators show a MACD buy signal and an RSI neutral market condition. • The company reported annual revenue of $34.30 billion with a net loss.

• Oracle faced selling pressure due to counterparty risks from AI partners. • Aggressive capital expenditures drove free cash flow into negative territory. • Supply chain hurdles and regulatory delays introduced operational execution risks.

• TTM Technologies announced a $400 million investment to expand Asian production facilities. • Investors reacted negatively due to capital intensity and lack of short-term guidance. • The stock faced profit-taking amid elevated valuations and geopolitical supply chain concerns.

• IonQ agreed to acquire Elisity in an all-stock transaction valued up to $1.3 billion. • Investors raised equity dilution concerns due to newly issued equity and limited financial disclosures. • Broader quantum sector peers declined amid macroeconomic pressures and elevated Treasury yields.

• Moderna shares declined as investors engaged in profit-taking following recent gains. • Wall Street analysts highlighted valuation friction due to unprofitability and high cash burn. • The company reported an annual revenue of $1.94B and a net loss.

Microsoft (MSFT) said it plans to deploy its next-generation in-house AI chip, Maia 300, in data centers starting next year and expand the deployment scale of the Maia series to several gigawatts, aiming to power its AI software primarily with in-house hardware and reduce reliance on Nvidia GPUs. The Maia chip is specifically designed for AI inference—using existing models to perform tasks such as summarizing meetings and answering research questions. Microsoft expects that compared to leading GPU systems, Maia 300 will generate 40% more tokens per megawatt. A token is the basic unit of measurement for AI output, typically corresponding to a word or part of a word; this metric measures output capacity per unit of power.

• Fabrinet faced downside volatility due to selling pressure in AI optical networking names. • Investors expressed apprehension over co-packaged optics impacting traditional pluggable module manufacturing demand. • Fabrinet maintains a debt-free balance sheet with an annual revenue of $4.64B.

• Fair Isaac rallied due to short-covering and positive cost-cutting responses. • Management announced a 15 percent workforce reduction and AI integration. • Core analytics and software platforms continued supporting strong gross margins.

• Astera Labs faced downward pressure from analyst downgrades and sector repricing. • Institutional selling and insider share sales reinforced short-term technical weakness. • Core connectivity products maintain momentum despite heightened gross margin scrutiny.

• Northland Securities downgraded Semtech to Market Perform due to elevated valuations. • An executive sold shares under a pre-arranged Rule 10b5-1 trading plan. • Semtech reports annual revenue of $1.05B and a net loss of $40.38M.

• Carvana faced downward pressure ahead of its third-quarter earnings report. • Declining per-unit profitability and high interest rates raised market concerns. • The stock's MACD indicates a sell signal while Williams %R suggests oversold.

Meta Platforms (META) launched its AI model Muse Wonder on Monday, claiming it possesses "frontier capabilities." The release will test the technological results of Meta’s multi-billion-dollar AI restructuring and reflects the company's push to generate AI revenue beyond its core advertising business. Internally codenamed "Watermelon," Muse Wonder is the company's most capable model since Mark Zuckerberg aggressively recruited talent and overhauled its AI operations. Meta stated that the model rivals OpenAI's ChatGPT and Anthropic's Claude in handling coding, financial, and legal tasks, and outperforms Claude Opus 5.5, Fable 5.1, and GPT-6 Astra on certain benchmarks.

• Ciena faced intraday volatility from profit-taking and valuation compression following a rally. • Supply chain bottlenecks continue to cap near-term revenue conversion speed and delivery timelines. • Annual revenue reached $4.77 billion while multiple analysts maintained Buy ratings.

• Bloom Energy shares retreated as investors took profits before the third-quarter earnings. • Project concentration risks and delayed deployment schedules introduced near-term revenue timing uncertainty. • High valuation multiples and macroeconomic headwinds amplified the stock's downside pressure.

• Nebius Group shares faced downward pressure amid deteriorating market sentiment toward AI infrastructure. • Concerns over equity dilution and insider share sales weighed heavily on investor sentiment. • The stock's technical indicators show neutral conditions alongside an oversold Williams %R reading.

• Cerebras Systems declined due to profit-taking and AI hardware valuation scrutiny. • Concerns over adoption and insider sales increased downward market pressure. • The stock features negative operating margins and high cash burn.

• Coherent Corp. faced valuation compression due to macroeconomic headwinds and profit-taking. • The company reported $7.12B annual revenue and $769.90M net profit. • Analysts maintain an average price target of $410.10 for the stock.

Brent crude (UKOIL) prices briefly touched $107 per barrel. Last Saturday, Houthi militants attacked King Khalid International Airport in Riyadh, the capital of Saudi Arabia, rapidly escalating market concerns over Middle East supply disruptions. According to Saudi official media outlet Saudi Gazette, Saudi Arabia's General Authority of Civil Aviation stated that the attack on Riyadh's King Khalid International Airport left 13 people dead and 309 injured. Earlier, an attack launched by the Houthis on the airport last Thursday killed three Saudi citizens, including a pilot.

• T-Mobile stock rebounded following an upgrade to Outperform by Raymond James. • Analysts dismissed competitive fears regarding satellite spectrum deals as excessive. • Institutional investors bought shares capitalizing on strong free cash flow metrics.

• Bristol-Myers Squibb stock fell despite positive Phase 3 clinical trial results. • RYZ101 met its endpoint, while admilparant showed mixed efficacy at different doses. • Technical indicators show a sell signal with an RSI of 29.182.